Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Acorda Therapeutics Shares Sunk 15% Today

By Todd Campbell - Dec 11, 2018 at 5:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Wall Street is increasingly concerned about this biotech stock's future.

What happened

Acorda Therapeutics (ACOR -3.06%) shares fell 15% on Tuesday to $16.16 following word Goldman Sachs cut its rating to "sell" and reduced its price target on the biotech by nearly 50% to $10 per share. 

So what

Goldman Sachs' pessimism stems from a recent court decision invalidating patents preventing generic competition to Ampyra, Acorda Therapeutics' multiple sclerosis drug.

A man sits on a sidewalk with head in hands in front of a wall showing a declining share price chart.


The patent decision is a big blow to because Amprya accounted for $543 million of the company's $588 million in revenue in 2017 and $138 million of its $140 million in revenue in the third quarter of 2018.

In addition to the prospect of declining revenue due to generic entrants, there's also uncertainty associated with the upcoming FDA decision on Inbrija, an inhaled formulation of levodopa, a Parkinson's disease drug. The FDA was expected to issue a decision on Inbrija in October; however, it pushed its decision back to Jan. 5. 

Now what

Acorda Therapeutics has said it thinks Inbrija's peak sales could reach $800 million someday. That may be an optimistic forecast, however, and even if it isn't, there's no certainty that the FDA will approve Inbrija. In August 2017, the FDA refused to file Acorda Therapeutics' initial application for Inbrija, requesting more information, and in September, it delayed its decision on the resubmitted application for Amprya so that it could review additional information it had requested from the company.

Absent an Inbrija green light, next year could be a tough year for sales at Acorda Therapeutics, so investors are probably best served watching this one from the sidelines until there's more clarity about Inbrija's future. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Acorda Therapeutics, Inc. Stock Quote
Acorda Therapeutics, Inc.
$0.66 (-3.06%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.